Exact Sciences Corporation $EXAS is Eagle Health Investments LP’s 10th Largest Position

Eagle Health Investments LP increased its holdings in shares of Exact Sciences Corporation (NASDAQ:EXAS) by 21.1% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 270,950 shares of the medical research company’s stock after acquiring an additional 47,200 shares during the period. Exact Sciences makes up about 3.9% of Eagle Health Investments LP’s portfolio, making the stock its 10th largest holding. Eagle Health Investments LP owned 0.14% of Exact Sciences worth $14,824,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of the business. Massachusetts Financial Services Co. MA purchased a new position in shares of Exact Sciences during the 2nd quarter valued at approximately $157,805,000. Holocene Advisors LP increased its holdings in Exact Sciences by 189.5% in the 2nd quarter. Holocene Advisors LP now owns 2,145,181 shares of the medical research company’s stock worth $113,995,000 after acquiring an additional 1,404,086 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. raised its position in Exact Sciences by 643.1% during the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,286,595 shares of the medical research company’s stock worth $70,390,000 after acquiring an additional 1,113,459 shares during the period. Norges Bank acquired a new position in Exact Sciences during the second quarter worth $48,372,000. Finally, AQR Capital Management LLC lifted its holdings in Exact Sciences by 73.3% during the second quarter. AQR Capital Management LLC now owns 1,753,283 shares of the medical research company’s stock valued at $93,169,000 after purchasing an additional 741,517 shares in the last quarter. Hedge funds and other institutional investors own 88.82% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on EXAS. Wolfe Research lowered Exact Sciences from a “strong-buy” rating to a “hold” rating in a research note on Thursday, November 20th. Wells Fargo & Company restated an “equal weight” rating and issued a $105.00 price objective (up previously from $85.00) on shares of Exact Sciences in a report on Thursday, November 20th. William Blair lowered Exact Sciences from an “outperform” rating to a “market perform” rating in a report on Thursday, November 20th. Robert W. Baird set a $105.00 target price on shares of Exact Sciences in a report on Thursday, November 20th. Finally, Craig Hallum downgraded shares of Exact Sciences from a “buy” rating to a “hold” rating and set a $105.00 price objective for the company. in a report on Friday, November 21st. Two equities research analysts have rated the stock with a Buy rating, twenty-one have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Exact Sciences has a consensus rating of “Hold” and a consensus price target of $89.56.

Exact Sciences Trading Up 0.1%

NASDAQ EXAS opened at $103.31 on Wednesday. The company has a debt-to-equity ratio of 0.93, a quick ratio of 2.44 and a current ratio of 2.72. The firm has a market cap of $19.71 billion, a price-to-earnings ratio of -93.92, a PEG ratio of 2.44 and a beta of 1.42. The firm has a 50 day simple moving average of $102.19 and a 200-day simple moving average of $76.75. Exact Sciences Corporation has a one year low of $38.81 and a one year high of $103.54.

Exact Sciences (NASDAQ:EXAS) last released its earnings results on Friday, February 13th. The medical research company reported ($0.21) earnings per share for the quarter, missing analysts’ consensus estimates of $0.08 by ($0.29). The firm had revenue of $878.38 million for the quarter, compared to analysts’ expectations of $860.59 million. Exact Sciences had a positive return on equity of 0.53% and a negative net margin of 6.40%.The firm’s quarterly revenue was up 23.1% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.06) earnings per share. Equities research analysts anticipate that Exact Sciences Corporation will post -0.58 EPS for the current fiscal year.

Exact Sciences Company Profile

Exact Sciences Corporation is a molecular diagnostics company headquartered in Madison, Wisconsin, dedicated to the early detection and prevention of cancer. The company’s flagship product, Cologuard®, is a noninvasive, stool-based DNA screening test for colorectal cancer that was developed in collaboration with the Mayo Clinic. By combining DNA mutation analysis with hemoglobin detection, Cologuard aims to improve screening adherence and identify cancers and precancerous lesions in average-risk adults.

Since its founding in 1995, Exact Sciences has expanded its portfolio through strategic acquisitions and internal research and development.